Phase 3 Readout

TARA: Phase 3 Topline: A Phase 2b/3 Randomized Open-Label Dose-Selection Study With Open-Label Extension and Randomized Dou

Name: Phase 3 Topline: A Phase 2b/3 Randomized Open-Label Dose-Selection Study With Open-Label Extension and Randomized Dou
Start: 2029-01-01
End: 2029-01-01

January 1, 2029. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: January 1, 2029
Company: Protara Therapeutics, Inc. (TARA)

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Readout~month

Phase 3 Topline: A Phase 2b/3 Randomized Open-Label Dose-Selection Study With Open-Label Extension and Randomized Dou

January 1, 2029

TARA overview →

Company: Protara Therapeutics, Inc. (TARA)
Indication: Choline Deficiency; Liver Injury